Drug intelligence / Profile preview

FLOVID-20

Development stage: Unknown
Lead developer: Flow Pharma
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Inhalation, Injection

Overview

**FLOVID-20** is Flow Pharma's investigational, FlowVax-based synthetic peptide T-cell vaccine and immunotherapy for prevention and treatment of COVID-19. The candidate presents conserved epitopes from the SARS-CoV-2 nucleocapsid protein to stimulate cytotoxic T-cell immunity against virus-infected cells, rather than relying primarily on spike-directed neutralizing antibodies. It is designed for inhaled or intramuscular administration and has been evaluated in nonhuman primates; Flow Pharma describes the program as under development, with manufacturing for clinical testing and a Phase 1/2 clinical-testing plan. ([flowpharma.com](https://flowpharma.com/product/flovid-20/))

Brand names: FLOVID-20FLOVID20FLOVID 20
Other names: FlowVax COVID-19

Targets

N (Nucleocapsid protein)

Beyond the preview

Go deeper on FLOVID-20.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FLOVID-20.

Explore the full profile